Review Article

Metabolic Basis for Thyroid Hormone Liver Preconditioning: Upregulation of AMP-Activated Protein Kinase Signaling

Luis A. Videla,1 Virginia Fernández,1 Pamela Cornejo,2 and Romina Vargas1

1Molecular and Clinical Pharmacology Program, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile
2Faculty of Medicine, Diego Portales University, Santiago, Chile

Correspondence should be addressed to Luis A. Videla, lvidela@med.uchile.cl

Received 5 March 2012; Accepted 17 April 2012

Academic Editors: H. M. Abu-Soud and D. Benke

Copyright © 2012 Luis A. Videla et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The liver is a major organ responsible for most functions of cellular metabolism and a mediator between dietary and endogenous sources of energy for extrapathic tissues. In this context, adenosine-monophosphate- (AMP-) activated protein kinase (AMPK) constitutes an intrahepatic energy sensor regulating physiological energy dynamics by limiting anabolism and stimulating catabolism, thus increasing ATP availability. This is achieved by mechanisms involving direct allosteric activation and reversible phosphorylation of AMPK, in response to signals such as energy status, serum insulin/glucagon ratio, nutritional stresses, pharmacological and natural compounds, and oxidative stress status. Reactive oxygen species (ROS) lead to cellular AMPK activation and downstream signaling under several experimental conditions. Thyroid hormone (L-3,3′,5-triiodothyronine, T3) administration, a condition that enhances liver ROS generation, triggers the redox upregulation of cytoprotective proteins affording preconditioning against ischemia-reperfusion (IR) liver injury. Data discussed in this work suggest that T3-induced liver activation of AMPK may be of importance in the promotion of metabolic processes favouring energy supply for the induction and operation of preconditioning mechanisms. These include antioxidant, antiapoptotic, and anti-inflammatory mechanisms, repair or resynthesis of altered biomolecules, induction of the homeostatic acute-phase response, and stimulation of liver cell proliferation, which are required to cope with the damaging processes set in by IR.

1. Introduction

In mammals, the liver is a major organ responsible for metabolic functions including most of the pathways for intermediary catabolism, glucose, lipoprotein, and plasma protein biosynthesis, biotransformation of xenobiotics, excretion, and secretion of different metabolites and mediators [1]. The liver functions as a mediator between dietary and endogenous sources of energy and extrahepatic organs that continuously require energy, mainly the brain and erythrocytes, under cycling conditions between fed and fasted states. In the fed state, where insulin action predominates, digestion-derived glucose is converted to pyruvate via glycolysis, which is oxidized to produce energy, whereas fatty acid oxidation is suppressed. Excess glucose can be either stored as hepatic glycogen or channelled into de novo lipogenesis. In the fasted state, considerable liver fuel metabolism changes occur due to decreased serum insulin/glucagon ratio, with higher glucose production as a consequence of stimulated glycogenolysis and gluconeogenesis (from alanine, lactate, and glycerol). Major enhancement in fatty acid oxidation also occurs to provide energy for liver processes and ketogenesis to supply metabolic fuels for extrapathic tissues [2]. For these reasons, the liver is considered as the metabolic processing organ of the body, and alterations in liver functioning affect whole-body metabolism and energy homeostasis. Moreover, understanding the signaling mechanisms regulating liver energy metabolism is crucial for the management of metabolic diseases or for developing preconditioning strategies aimed at preventing organ injury [1].

In this context, adenosine-monophosphate- (AMP-) activated protein kinase (AMPK) is the downstream component of a protein kinase cascade acting as an intracellular
2. Liver AMPK: Structure and Regulation

AMPK, a serine/threonine kinase, is a heterotrimeric complex comprising a catalytic subunit α and two regulatory subunits β and γ involved in heterotrimer formation and ligand sensing (Figure 1). The α subunit has a threonine residue (Thr172) within the activation loop of the kinase domain, with the C-terminal region being required for association with β and γ subunits. The β subunit associates with α and γ by means of its C-terminal region [6], whereas the γ subunit has four cystathionine β-synthase (CBS) motifs, which bind AMP or ATP in a competitive manner [7].

Regulation of liver AMPK activity involves both direct allosteric activation and reversible phosphorylation. AMPK is allosterically activated by AMP through binding to the regulatory subunit-γ, which induces a conformational change in the kinase domain of subunit α that protects AMPK from dephosphorylation of Thr172 [8], probably by protein phosphatase-2C [9] (Figure 1(A)). Activation of AMPK requires phosphorylation of Thr172 in its α subunit, which can be attained by either (i) tumor suppressor LKB1 kinase following enhancement in the AMP/ATP ratio [10], a kinase that plays a crucial role in AMPK-dependent control of liver glucose and lipid metabolism [11]; (ii) Ca2+-calmodulin-dependent protein kinase kinase-β (CaMKKβ) that phosphorylates AMPK in an AMP-independent, Ca2+-dependent manner [12]; (iii) transforming growth-factor-β-activated

![Figure 1: Regulation of AMP-activated protein kinase (AMPK) by (A) direct allosteric activation and (B) reversible phosphorylation and downstream responses maintaining intracellular energy balance. Abbreviations: LKB1, tumor suppressor LKB1 kinase; CaMKKβ, Ca2+-calmodulin-dependent kinase kinase-β; TAK1, transforming growth-factor-β-activated kinase-1.](image-url)
kinase-1 (TAK1) [13] (Figure 1(B)), an important kinase in hepatic Toll-like receptor 4 signaling in response to lipopolysaccharide [14]. Among these kinases, the relevance of CaMKKβ and TAK1 in liver AMPK activation remains to be established in metabolic stress conditions. Both allosteric and phosphorylation mechanisms are able to elicit over 1000-fold increase in AMPK activity [15], thus allowing the liver to respond to small changes in energy status in a highly sensitive fashion (Figure 1).

Liver AMPK is activated in response to different metabolic stresses, including those that increase ATP utilization (activation of biosynthetic pathways) or that reduce ATP production (hypoxia, glucose deprivation, inhibition of mitochondrial oxidative phosphorylation) [16]. A clear example of liver AMPK modulation occurs in the transition from fasted to fed state, which implies physiological changes in energy dynamics. During refeeding, liver AMPKα1 activity is decreased within 1 h, an effect that is exacerbated for both AMPKα1 and AMPKα2 isoforms in the 1 to 24 h period [17]. These changes are compatible with the increase in plasma insulin, reported to reduce hepatic AMPK activity, and diminution in glucagon, shown to activate hepatic AMPK. Besides, liver AMPK can be regulated by ghrelin, glucocorticoids, and the adipokines resistin and adiponectin, in addition to pharmacological and natural drugs including polyphenols, 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR), and the antidiabetic drugs metformin and thiazolidinediones [2].

In addition to rapid AMPK regulation through allosterism and reversible phosphorylation, long-term effects of AMPK activation induce changes in hepatic gene expression. This was demonstrated for (i) the transcription factor carbohydrate-response element-binding protein (ChREBP), whose Ser568 phosphorylation by activated AMPK blocks its DNA binding capacity and glucose-induced gene transcription under hyperlipidemic conditions [18]; (ii) liver sterol regulatory element-binding protein-1c (SREBP-1c), whose mRNA and protein expression and those of its target gene for fatty acid synthase (FAS) are reduced by metformin-induced AMPK activation, decreasing lipogenesis and increasing fatty acid oxidation due to malonyl-CoA depletion [19]; (iii) transcriptional coactivator transducer of regulated CREB activity-2 (TORC2), a crucial component of the hepatic gluconeogenic program, was reported to be phosphorylated by activated AMPK. This modification leads to subsequent cytoplasmatic sequestration of TORC2 and inhibition of gluconeogenic gene expression [20], a mechanism underlying the plasma glucose-lowering effects of adiponectin and metformin through AMPK activation by upstream LKB1 [21]. Interestingly, the polyphenol epigallocatechin-3-gallate- (EGCG-) induced AMPK-dependent repression of gluconeogenic genes is mediated by an LKB1-independent pathway, relying on CaMKKβ activation through generation of reactive oxygen species (ROS) [22].

In conclusion, activation of AMPK in the liver is a key regulatory mechanism controlling glucose and lipid metabolism, inhibiting anabolic processes, and enhancing catabolic pathways in response to different signals, including energy status, serum insulin/glucagon ratio, nutritional stresses, pharmacological and natural compounds, and oxidative stress status.

3. Reactive Oxygen Species (ROS) and AMPK Activation

The high energy demands required to cope with all the metabolic functions of the liver outlined in the INTRODUCTION are met by fatty acid oxidation under conditions of both normal blood glucose levels and hypoglycemia, whereas glucose oxidation is favoured in hyperglycemic states, with consequent generation of ROS [1]. Due to the electronic structure of oxygen in the ground state, one-electron transfer reactions occur, leading to the generation of ROS such as superoxide radical (O2•−), hydrogen peroxide (H2O2), and hydroxyl radical (HO•). In addition, secondary ROS are produced, including alkoxyl (RO•) and peroxyl (ROO•) radicals or hydroperoxides (ROOH) derived from biomolecules (R), hypochlorous acid (HClO), and the electronically exited state singlet oxygen (O2∗) [23, 24]. At the cellular level, ROS lead to a wide spectrum of responses depending (i) on the cell type, with different cells differing in the basal antioxidant status, (ii) the level of ROS achieved, and (iii) the duration of the exposure [23, 24]. Under normal conditions, ROS occur at relatively low levels due to their fast processing by antioxidant mechanisms, whereas at acute or prolonged high ROS levels, severe oxidation of biomolecules and dysregulation of signal transduction and gene expression is achieved, with consequent cell death through necrotic and/or apoptotic-signaling pathways. On the other hand, transient and moderate ROS generation may trigger signals regulating either protein function, through reversible oxidation or nitrosation of protein sulfhydryls, and/or gene expression, via modulation of the activity of specific protein kinases, protein phosphatases, or redox-sensitive transcription factors, with induction of cytoprotective responses [23–25].

AMPK is activated by several physiological and pathological conditions that are characterized by concomitant ROS generation, such as heat shock in isolated hepatocytes [26], hypoxia/ischemia in heart muscle [27], exercise in skeletal muscle [28], and ATP depletion through mitochondrial electron flow inhibition by antimycin A or azide [29]. However, direct regulation of AMPK by ROS was first reported by Choi et al. [30] using H2O2 (25 to 600 μM) in NIH-3T3 cells, in association with increased AMP/ATP ratios and AMPKα1-Thr172 phosphorylation. Although these events were blocked by pretreatment with the potent free-radical scavenger dimethyl sulfoxide [30], the nature of the upstream kinase(s) activating AMPK was not established, although 1 mM H2O2 AMPK stimulation via CaMKKβ activation in fibroblasts from LKB1−/− mice has been reported [31]. In addition, AMPK activation is observed in different cell-cultures exposed to 10 μM to 1 mM H2O2 [32] showing N-acetylcysteine (NAC) sensitivity [33], or under conditions of low glucose concentrations triggering mitochondrial ROS production [34]. Interestingly, AMPK activation under hypoxic conditions was proposed to be induced by enhancement in the AMP/ATP ratio [16];
however, recent data demonstrate that as cellular $O_2$ levels decrease, mitochondrial complex III acts as an $O_2$-sensor by releasing ROS into the intermembrane space, which upon diffusion into the cytosol trigger AMPK activation [35].

Phytochemicals have been shown to be involved in regulation of a variety of metabolic processes, with therapeutic effects for obesity, diabetes, and cardiovascular diseases, including green tea EGCG, red pepper capsaicin, and soybean genistein [22, 36], polyphenols that generate ROS related to free-radical-induced chain reactions [37]. Due to this feature, activation of the AMPK signaling pathway is achieved by genistein, EGCG, and capsaicin as an NAC-sensitive response [36, 38]. However, in these studies the upstream kinase(s) involved in AMPK phosphorylation was not established. Furthermore, mouse hepatocytes subjected to EGCG exhibit increased ROS generation in the presence of NADPH, leading to AMPK phosphorylation through upstream CaMKKβ and suppression of hepatic gluconeogenesis [22]. Hepatocyte AMPK activation by EGCG is suppressed by a cell membrane permeable catalase that eliminates $H_2O_2$; however, the mechanism of CaMKKβ activation by ROS remains to be determined. In this model system, EGCG did not induce phosphorylation of LKB1, an alternate candidate kinase for AMPK activation [22].

In conclusion, ROS trigger cellular AMPK activation under different experimental conditions, including (i) direct \textit{in vitro} $H_2O_2$ addition to cell cultures, (ii) \textit{in vitro} and \textit{in vivo} conditions underlying ROS generation, or (iii) ROS production coupled to free-radical chain reactions induced by polyphenols, with responses being time and concentration dependent.

4. Thyroid Hormone (L-3,3′,5-Triiodothyronine, $T_3$), Metabolic Regulation, and ROS Production

$T_3$ is important for the normal function of most mammalian tissues, with major actions on $O_2$ consumption and metabolic rate, thus determining enhancement in fuel consumption for oxidation processes and ATP repletion [1]. $T_3$ acts predominantly through nuclear receptors (TR) $\alpha$ and $\beta$, forming functional complexes with retinoic X receptor that bind to thyroid hormone response elements (TRE) to activate gene expression [39]. $T_3$ calorigenesis is primarily due to the induction of enzymes related to mitochondrial electron transport and ATP synthesis, catabolism, and some anabolic processes via upregulation of genomic mechanisms [40]. The net result of this $T_3$ action is the enhancement in the rate of $O_2$ consumption of target tissues such as liver, which may be contributed by secondary processes induced by $T_3$ such as (i) energy expenditure due to higher active cation transport, (ii) energy loss due to futile cycles coupled to increase in catabolic and anabolic pathways [41], and (iii) $O_2$ equivalents used in hepatic ROS generation both in hepatocytes and Kupffer cells [40]. In addition, $T_3$-induced higher rates of mitochondrial oxidative phosphorylation are likely to induce higher levels of ATP, which are partially balanced by intrinsic uncoupling afforded by induction of uncoupling proteins by $T_3$ [42]. In agreement with this view, the cytosolic ATP/ADP ratio is decreased in hyperthyroid tissues, due to simultaneous stimulation of ATP synthesis and consumption [43].

Although $T_3$ influences most pathways of intermediary metabolism, actions on lipid metabolism are particularly relevant. In this respect, $T_3$ accelerates TG turnover and chylomicron clearance rate [44], with fatty acids derived from adipose tissue lipolysis being the primary source of substrate for $T_3$-induced calorigenesis via $\beta$-oxidation, and whereas the early increase in lipogenesis serves simply to maintain fat stores [45]. Thus, the concentration and turnover of free fatty acids are increased in hyperthyroidism, resulting from a $T_3$-induced increase in (i) lipolysis, as the result of higher adipose tissue sensitivity to lipolytic hormones, and (ii) fatty acid $\beta$-oxidation to $CO_2$ as well as to ketone bodies [44]. Regulation of fatty acid oxidation is mainly attained by carnitine palmitoyltransferase $\iota$ ($CPT-I\alpha$), catalyzing the transport of fatty acids from cytosol to mitochondria for $\beta$-oxidation, and acyl-CoA oxidase (ACO), catalyzing the first rate-limiting reaction of peroxisomal $\beta$-oxidation, enzymes that are induced by both $T_3$ and peroxisome proliferator-activated receptor $\alpha$ (PPAR-$\alpha$) [46, 47]. Furthermore, PPAR-$\alpha$-mediated upregulation of CPT-I$\alpha$ mRNA is enhanced by PPAR-$\gamma$ coactivator $\iota$ ($PGC-1\alpha$), which in turn augments $T_3$ induction of CPT-I$\alpha$ expression [48]. Interestingly, PGC-1$\alpha$ is induced by $T_3$ [49], AMPK activation [33], and ROS [50], thus establishing potential links between $T_3$ action, ROS generation, and AMPK activation with the onset of mitochondrial biogenesis and fatty acid $\beta$-oxidation.

Enhancement in cellular $O_2$ consumption by $T_3$ increases ROS production at several subcellular sites of hepatocytes and in the respiratory burst of Kupffer cells (Figure 2) [40]. Liver ROS generation leads to activation of the transcription
Factors nuclear factor-κB (NF-κB), activating protein 1 (AP-1), and signal transducer and activator of transcription 3 (STAT3) at the Kupffer cell level, with upregulation of cytokine expression (TNF-α, IL-1, IL-6), which upon interaction with specific receptors in hepatocytes trigger the expression of cytoprotective proteins (Figure 3(A)). These responses and the promotion of hepatocyte and Kupffer-cell proliferation represent hormetic effects reestablishing redox homeostasis, promoting cell survival, and protecting the liver against ischemia-reperfusion injury [51]. T₃ liver preconditioning also involves the activation of the Nrf2-Keap1 defense pathway [52, 53], upregulating antioxidant proteins, phase-2 detoxifying enzymes, and multidrug resistance proteins, members of the ATP binding cassette (ABC) superfamily of transporters (Figure 3(B)) [24, 54]. In agreement with T₃-induced liver preconditioning, T₃ or L-thyroxin afford preconditioning against IR injury in the heart, in association with activation of protein kinase C [55] and attenuation of p38 and c-Jun-N-terminal kinase activation [56], and in the kidney, in association with heme oxygenase-1 upregulation [57].

In conclusion, T₃ is a key metabolic regulator coordinating short-term and long-term energy needs [39], with major actions on liver metabolism. These include promotion of (i) gluconeogenesis and hepatic glucose production, and (ii) fatty acid oxidation coupled to enhanced adipose tissue lipolysis, with higher fatty acid flux to the liver and consequent ROS production (Figure 2) and redox upregulation of cytoprotective proteins affording liver preconditioning (Figure 3).
of a single dose of 0.1 mg T₃/kg to rats activates liver AMPK (Figure 4; unpublished work). Western blot analysis of hepatic AMPK showed enhancement in phosphorylated AMPK (AMPK-OP) over control values at time zero; b effects involving AMPK and Akt/PKB, thus mediating uptake and oxidation of both glucose and fatty acids [59]. In studies under different experimental conditions, T₃ was reported to upregulate the expression of muscle AMPK [60, 61], leading to AMPK activation by phosphorylation [60–64], with concomitant phosphorylation of the AMPK target protein acetyl-CoA carboxylase (ACC) [60, 63, 64]. Skeletal muscle AMPK activation is characterized by (i) being a rapid and transient response [62, 63], (ii) upstream activation by Ca²⁺-induced mobilization and CaM KKβ activation [64], (iii) upstream upregulation of LKB1 expression, which requires association with STRAD and MO25 for optimal phosphorylation/activation of AMPK [61, 65], and (iv) stimulation of mitochondrial fatty acid β-oxidation [60, 64]. In addition to these effects, T₃-induced muscle AMPK activation was found to trigger two major downstream signaling pathways, namely, (i) peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) mRNA expression [63] and phosphorylation [61], a transcriptional regulator for genes related to mitochondrial biogenesis, fatty acid oxidation, and gluconeogenesis [66] and (ii) cyclic AMP response element binding protein (CREB) phosphorylation [61], which in turn induces PGC-1α expression in liver tissue [67], thus reinforcing mechanism (i). These data indicate that AMPK phosphorylation of PGC-1α initiates many of the important gene regulatory functions of AMPK in skeletal muscle [68].

In heart, hyperthyroidism increased glycolysis and sarcolemmal GLUT4 levels by the combined effects of AMPK activation and insulin stimulation, with concomitant increase in fatty acid oxidation that is proportional to enhanced cardiac mass and contractile function [69].

6. Thyroid Hormone, AMPK Activation, and Liver Preconditioning

Recent studies by our group revealed that administration of a single dose of 0.1 mg T₃/kg to rats activates liver AMPK (Figure 4; unpublished work). Western blot analysis of hepatic AMPK showed enhancement in phosphorylated AMPK/nonphosphorylated AMPK ratios in T₃-treated rats over control values, an effect that is significant in the time period of 1 to 48 hours after hormone treatment (Figure 4). Administration of a substantially higher dose (0.4 mg T₃/kg) resulted in decreased liver AMPK activation at 4 h to return to control values at 6 h after treatment [63], a dose that may induce adverse effects in the liver associated with the thyrotoxicosis state developed [70].
Activation of liver AMPK by T₃ may be of relevance in terms of promotion of fatty acid oxidation for ATP supply, supporting hepatoprotection against IR injury (Figure 3(C)). This proposal is based on the high energy demands underlying effective liver preconditioning for full operation of hepatic antioxidant, antiapoptotic, and anti-inflammatory mechanisms [71, 72], oxidized biomolecules repair or resynthesis [24, 40], induction of the homeostatic acute-phase response [73], and promotion of hepatocyte [74] and Kupffer cell [75] proliferation, mechanisms that are needed to cope with the damaging processes set in by IR [76–78]. T₃ liver preconditioning [51, 74, 79], in addition to that afforded by n-3 long-chain polyunsaturated fatty acids given alone [80, 81] or combined with T₃ at lower dosages [82], or by iron supplementation [83], constitutes protective strategies against hepatic IR injury that may have clinical application in human liver transplantation and hepatic resections. This is a most important issue considering that pharmacological approaches, gene therapy, and strategies underlying chemically induced moderate oxidative stress development have not reached the clinical setting due to toxicity problems, side effects, or difficulties in implementation, with the exception of ischemic preconditioning that remains controversial at present time [80, 84]. For these reasons, studies on the molecular mechanisms underlying T₃-induced liver AMPK activation (Figure 4) are currently under assessment in our laboratory, information that precedes the future design of protocols assessing T₃ effects in IR-related injury in human liver surgery.

**Acknowledgment**

The authors thank FONDECYT (Grant 1120034) for financial support.

**References**

[1] V. Fernández and L. A. Videlia, “Kupffer cell-dependent signaling in thyroid hormone carorigenesis: possible applications for liver preconditioning,” *Current Signal Transduction Therapy*, vol. 4, no. 2, pp. 144–151, 2009.

[2] B. Violette, B. Guigas, J. Leclerc et al., “AMP-activated protein kinase in the regulation of hepatic energy metabolism: from physiology to therapeutic perspectives,” *Acta Physiologica*, vol. 196, no. 1, pp. 81–98, 2009.

[3] D. Carling, “The AMP-activated protein kinase cascade - A unifying system for energy control,” *Trends in Biochemical Sciences*, vol. 29, no. 1, pp. 18–24, 2004.

[4] B. E. Kemp, D. Stapleton, D. J. Campbell et al., “AMP-activated protein kinase, super metabolic regulator,” *Biochemical Society Transactions*, vol. 31, no. 1, pp. 162–168, 2003.

[5] D. G. Hardie, “AMP-activated protein kinase-an energy sensor that regulates all aspects of cell function,” *Genes and Development*, vol. 25, no. 18, pp. 1895–1908, 2011.

[6] A. Woods, P. C. F. Cheung, F. C. Smith et al., “Characterization of AMP-activated protein kinase β subunits Assembly of the heterotrimeric complex in vitro,” *Journal of Biological Chemistry*, vol. 271, no. 17, pp. 10282–10290, 1996.

[7] B. Xiao, R. Heath, P. Saiu et al., “Structural basis for AMP binding to mammalian AMP-activated protein kinase,” *Nature*, vol. 449, no. 7161, pp. 496–500, 2007.

[8] U. Riek, R. Scholz, P. Konarev et al., “Structural properties of AMP-activated protein kinase: dimerization, molecular shape, and changes upon ligand binding,” *Journal of Biological Chemistry*, vol. 283, no. 26, pp. 18331–18343, 2008.

[9] M. J. Sanders, P. O. Grondin, B. D. Hegarty, M. A. Snowden, and D. Carling, “Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade,” *Biochemical Journal*, vol. 403, no. 1, pp. 139–148, 2007.

[10] A. Woods, S. R. Johnstone, K. Dickerson et al., “LKB1 is the upstream kinase in the AMP-activated protein kinase cascade,” *Current Biology*, vol. 13, no. 22, pp. 2004–2008, 2003.

[11] K. Imai, K. Inukai, Y. Ikegami, T. Awata, and S. Katayama, “LKB1, an upstream AMPK kinase, regulates glucose and lipid metabolism in cultured liver and muscle cells,” *Biochemical and Biophysical Research Communications*, vol. 351, no. 3, pp. 595–601, 2006.

[12] S. A. Hawley, D. A. Pan, K. J. Mustard et al., “Calmodulin-dependent protein kinase kinase-β is an alternative upstream kinase for AMP-activated protein kinase,” *Cell Metabolism*, vol. 2, no. 1, pp. 9–19, 2005.

[13] M. Xie, D. Zhang, J. R. B. Dyck et al., “A pivotal role for endogenous TGF-β-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, no. 46, pp. 17378–17383, 2006.

[14] M. S. Hayden and S. Ghosh, “Signaling to NF-xb”, *Genes and Development*, vol. 18, no. 18, pp. 2195–2224, 2004.

[15] M. Suter, U. Riek, R. Tuerk, U. Schlattner, T. Wallimann, and D. Neumann, “Dissecting the role of 5'-AMP for allosteric stimulation, activation, and deactivation of AMP-activated protein kinase,” *Journal of Biological Chemistry*, vol. 281, no. 43, pp. 32207–32216, 2006.

[16] M. C. Towler and D. G. Hardie, “AMP-activated protein kinase in metabolic control and insulin signaling,” *Circulation Research*, vol. 100, no. 3, pp. 328–341, 2007.

[17] M. M. Assifi, G. Suchankova, S. Constant, M. Prentki, A. K. Saha, and N. B. Ruderman, “AMP-activated protein kinase and coordination of hepatic fatty acid metabolism of starved/carbohydrate-refed rats,” *American Journal of Physiology, Endocrinology and Metabolism*, vol. 289, no. 5, pp. E794–E800, 2005.

[18] T. Kawaguchi, K. Osatomi, H. Yamashita, T. Kabashima, and K. Uyeda, “Mechanism for fatty acid "sparing" effect on glucose-induced transcription: regulation of carbohydrate-responsive element-binding protein by AMP-activated protein kinase,” *Journal of Biological Chemistry*, vol. 277, no. 6, pp. 3829–3835, 2002.

[19] G. Zhou, R. Myers, Y. Li et al., “Role of AMP-activated protein kinase in mechanism of metformin action,” *Journal of Clinical Investigation*, vol. 108, no. 8, pp. 1167–1174, 2001.

[20] S. H. Koo, L. Flechner, L. Qi et al., “The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism,” *Nature*, vol. 437, no. 7062, pp. 1109–1114, 2005.

[21] R. J. Shaw, K. A. Lamia, D. Vasquez et al., “Medicine: the kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin,” *Science*, vol. 310, no. 5754, pp. 1642–1646, 2005.

[22] Q. F. Collins, H. Y. Liu, J. Pi, Z. Liu, M. J. Quon, and W. Cao, “Epigallocatechin-3-gallate (EGCG), a green tea polyphenol, suppresses hepatic gluconeogenesis through 5'-AMP-activated protein kinase,” *Journal of Biological Chemistry*, vol. 282, no. 41, pp. 30143–30149, 2007.
[23] W. Dröge, “Free radicals in the physiological control of cell function,” *Physiological Reviews*, vol. 82, no. 1, pp. 47–95, 2002.

[24] L. A. Videla, “Cytoprotective and suicidal signaling in oxidative stress,” *Biological Research*, vol. 43, no. 3, pp. 363–369, 2010.

[25] G. Poli, G. Leonardiuzzi, F. Biasi, and E. Chiarpotto, “Oxidative stress and cell signalling,” *Current Medicinal Chemistry*, vol. 11, no. 9, pp. 1163–1182, 2004.

[26] J. M. Corton, J. G. Gillespie, and D. G. Hardie, “Role of the AMP-activated protein kinase in the cellular stress response,” *Current Biology*, vol. 4, no. 4, pp. 315–324, 1994.

[27] N. Kudo, A. J. Barr, R. L. Barr, S. Desai, and G. D. Lopaschuk, “High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5’-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase,” *Journal of Biological Chemistry*, vol. 270, no. 29, pp. 17513–17524, 1995.

[28] W. W. Winder and D. G. Hardie, “Inactivation of acetyl-CoA carboxylase and activation of AMP-activated protein kinase in muscle during exercise,” *American Journal of Physiology, Endocrinology and Metabolism*, vol. 270, no. 2, pp. E299–E304, 1996.

[29] L. A. Witters, A. C. Nordlund, and L. Marshall, “Regulation of intracellular acetyl-CoA carboxylase by ATP depleters mimics the action of the 5’-AMP-activated protein kinase,” *Biochemical and Biophysical Research Communications*, vol. 181, no. 3, pp. 1486–1492, 1991.

[30] S. L. Choi, S. J. Kim, K. T. Lee et al., “The regulation of AMP-activated protein kinase by H2O2,” *Biochemical and Biophysical Research Communications*, vol. 287, no. 1, pp. 92–97, 2001.

[31] A. Woods, K. Dickerson, R. Heath et al., “Ca2+/calmodulin-dependent protein kinase kinase-1 acts upstream of AMP-activated protein kinase in mammalian cells,” *Cell Metabolism*, vol. 2, no. 1, pp. 21–33, 2005.

[32] I. J. Park, J. T. Hwang, M. K. Young, J. Ha, and J. P. Ock, “Differential modulation of AMPK signalling pathways by low or high levels of exogenous reactive oxygen species in colon cancer cells,” *Annals of the New York Academy of Sciences*, vol. 1091, pp. 102–109, 2006.

[33] I. Irrcher, V. Ljubicic, and D. A. Hood, “Interactions between ROS and AMP kinase activity in the regulation of PGC-1α transcription in skeletal muscle cells,” *American Journal of Physiology, Cell Physiology*, vol. 296, no. 1, pp. C116–C123, 2009.

[34] Y. Cai, G. A. Martens, S. A. Hinke, H. Heinberg, D. Pipeleers, and M. Van de Casteele, “Increased oxygen radical formation and mitochondrial dysfunction mediate beta cell apoptosis under conditions of AMP-activated protein kinase stimulation,” *Free Radical Biology and Medicine*, vol. 42, no. 1, pp. 64–78, 2007.

[35] B. M. Emerling, F. Weinberg, C. Snyder et al., “Hypoxic activation of AMPK is dependent on mitochondrial ROS but independent of an increase in AMP/ATP ratio,” *Free Radical Biology and Medicine*, vol. 46, no. 10, pp. 1386–1391, 2009.

[36] J. T. Hwang, I. J. Park, J. I. Shin et al., “Genistein, EGCG, and capsaicin inhibit adipocyte differentiation process via activating AMP-activated protein kinase,” *Biochemical and Biophysical Research Communications*, vol. 338, no. 2, pp. 694–699, 2005.

[37] S. Qanungo, M. Das, S. Haldar, and A. Basu, “Epigallocatechin-3-gallate induces mitochondrial membrane depolarization and caspase-dependent apoptosis in pancreatic cancer cells,” *Carcinogenesis*, vol. 26, no. 5, pp. 958–967, 2005.

[38] J. T. Hwang, J. Ha, I. J. Park et al., “Aptoptotic effect of EGCG in HT-29 colon cancer cells via AMPK signal pathway,” *Cancer Letters*, vol. 247, no. 1–2, pp. 115–121, 2007.

[39] Y. Y. Liu and G. A. Brent, “Thyroid hormone crosstalk with nuclear receptor signaling in metabolic regulation,” *Trends in Endocrinology and Metabolism*, vol. 21, no. 3, pp. 166–173, 2010.

[40] L. A. Videla, “Hormetic responses of thyroid hormone calorigenesis in the liver: association with oxidative stress,” *IUBMB Life*, vol. 62, no. 6, pp. 460–466, 2010.

[41] S. Soboll, “Thyroid hormone action on mitochondrial energy transfer,” *Biochimica et Biophysica Acta - Bioenergetics*, vol. 1144, no. 1, pp. 1–16, 1993.

[42] A. Lanni, M. Moreno, A. Lombardi, and F. Goglia, “Thyroid hormone and uncoupling proteins,” *FEBS Letters*, vol. 543, no. 1–3, pp. 5–10, 2003.

[43] M. J. Müller and H. J. Seitz, “Thyroid hormone action on intermediary metabolism. Part I: respiration, thermogenesis and carbohydrate metabolism,” *Klinische Wochenschrift*, vol. 62, no. 1, pp. 11–18, 1984.

[44] M. J. Müller and H. J. Seitz, “Thyroid hormone action on intermediary metabolism. Part II: lipid metabolism in hypo- and hyperthyroidism,” *Klinische Wochenschrift*, vol. 62, no. 2, pp. 49–55, 1984.

[45] J. H. Oppenheimer, H. L. Schwartz, J. T. Lane, and M. P. Thompson, “Functional relationship of thyroid hormone-induced lipogenesis, lipidolysis, and thermogenesis in the rat,” *Journal of Clinical Investigation*, vol. 87, no. 1, pp. 125–132, 1991.

[46] J. F. Louet, C. Le May, J. P. Pégourier, J. F. Decaux, and J. Girard, “Regulation of liver carnitine palmitoyltransferase I gene expression by hormones and fatty acids,” *Biochemical Society Transactions*, vol. 29, no. 2, pp. 310–316, 2001.

[47] L. Napal, P. F. Marrero, and D. Haro, “An intronic peroxisome proliferator-activated receptor-binding sequence mediates fatty acid induction of the human carnitine palmitoyltransferase 1A,” *Journal of Molecular Biology*, vol. 354, no. 4, pp. 751–759, 2005.

[48] Y. Zhang, K. Ma, S. Song, M. B. Elam, G. A. Cook, and E. A. Park, “ Peroxisomal proliferator-activated receptor-γ coactivator-1α (PGC-1α) enhances the thyroid hormone induction of carnitine palmitoyltransferase I (CPT-Iα),” *Journal of Biological Chemistry*, vol. 279, no. 52, pp. 53963–53971, 2004.

[49] I. Irrcher, P. J. Adhiketty, T. Sheehan, A. M. Joseph, and D. A. Hood, “PPARγ coactivator-1α expression during thyroid hormone- and contractile activity-induced mitochondrial adaptations,” *American Journal of Physiology - Cell Physiology*, vol. 284, no. 6, pp. C1669–C1677, 2003.

[50] J. St-Pierre, S. Drori, M. Uldry et al., “ Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators,” *Cell*, vol. 127, no. 2, pp. 397–408, 2006.

[51] V. Fernández, I. Castillo, G. Tapia et al., “Thyroid hormone preconditioning: protection against ischemia-reperfusion liver injury in the rat,” *Hepatology*, vol. 45, no. 1, pp. 170–177, 2007.

[52] P. Romanque, P. Cornejo, S. Valdés, and L. A. Videla, “Thyroid hormone administration induces rat liver Nrf2 activation: suppression by N-acetylcysteine pretreatment,” *Thyroid*, vol. 21, no. 6, pp. 635–662, 2011.
I. Irrcher, D. R. Walkinshaw, T. E. Sheehan, and D. A. Hood, M. Yamauchi, F. Kambe, X. Cao et al., “Thyroid hormone-induced cytosome-to-nuclear translocation of rat liver Nrfl2 is dependent on Kupffer-cell functioning,” *The Scientific World Journal*. In press.

M. Kobayashi and M. Yamamoto, “Molecular mechanisms activating the Nrfl2-Kcp1 pathway of antioxidant gene regulation,” *Antioxidants and Redox Signaling*, vol. 7, no. 3-4, pp. 385–394, 2005.

C. I. Pantos, V. A. Malliopoulou, I. S. Mourouzis et al., “Long-term thyroxine administration protects the heart in a pattern similar to ischemic preconditioning,” *Thyroid*, vol. 12, no. 4, pp. 325–329, 2002.

C. Pantos, V. Malliopoulou, I. Paizis et al., “Thyroid hormone and cardioprotection: study of p38 MAPK and JNKs during ischaemia and at reperfusion in isolated rat heart,” *Molecular and Cellular Biochemistry*, vol. 242, no. 1-2, pp. 173–180, 2003.

F. Li, S. Lu, R. Zhu et al., “Heme oxygenase-1 is induced by thyroid hormone and involved in thyroid hormone preconditioning-induced protection against renal warm ischemia in rat,” *Molecular and Cellular Endocrinology*, vol. 339, no. 1-2, pp. 54–62, 2011.

E. Silvestri, L. Burrone, P. De Lange et al., “Thyroid-state influence on protein-expression profile of rat skeletal muscle,” *Journal of Proteome Research*, vol. 6, no. 8, pp. 3187–3196, 2007.

D. G. Hardie, “AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy,” *Nature Reviews Molecular Cell Biology*, vol. 8, no. 10, pp. 774–785, 2007.

S. H. Park, S. R. Paulsen, S. R. Gammon, K. J. Mustard, D. G. Hardie, and W. W. Winder, “Effects of thyroid state on AMP-activated protein kinase and acetyl-CoA carboxylase expression in muscle,” *Journal of Applied Physiology*, vol. 93, no. 6, pp. 2081–2088, 2002.

D. J. Branvold, D. R. Allred, D. J. Beckstead et al., “Thyroid hormone effects on LKB1, MO25, phospho-AMPK, phospho-CREB, and PGC-1α in rat muscle,” *Journal of Applied Physiology*, vol. 105, no. 4, pp. 1218–1227, 2008.

P. De Lange, R. Senese, F. Gioffì et al., “Rapid activation by 3,5,3′-L-triiodothyronine of adenosine 5′-monophosphate-activated protein kinase/acetyl-coenzyme A carboxylase and Akt/protein kinase B signaling pathways: relation to changes in fuel metabolism and myosin heavy-chain protein content in rat gastrocnemius muscle in vivo,” *Endocrinology*, vol. 149, no. 12, pp. 6462–6470, 2008.

I. Irrcher, D. R. Walkinshaw, T. E. Sheehan, and D. A. Hood, “Thyroid hormone (T3) rapidly activates p38 and AMPK in skeletal muscle in vivo,” *Journal of Applied Physiology*, vol. 104, no. 1, pp. 178–185, 2008.

Yamauchi, K. Kambe, X. Cao et al., “Thyroid hormone activates adenosine 5′-monophosphate-activated protein kinase via intracellular calcium mobilization and activation of calcium/calmodulin-dependent protein kinase β,” *Molecular Endocrinology*, vol. 22, no. 4, pp. 893–903, 2008.

J. Boudeau, A. F. Baas, M. Deak et al., “MO25α/β interact with STRADαβ enhancing their ability to bind, activate and localize LKB1 in the cytoplasm,” *EMBO Journal*, vol. 22, no. 19, pp. 5102–5114, 2003.

P. Sadana and E. A. Park, “Characterization of the transactivation domain in the peroxisome proliferator-activated receptor γ co-activator (PGC-1),” *Biochemical Journal*, vol. 403, no. 3, pp. 511–518, 2007.

S. Herzig, F. Long, U. S. Jhala et al., “CREB regulates hepatic gluconeogenesis through the coactivator PGC-1,” *Nature*, vol. 413, no. 6852, pp. 179–183, 2001.

S. Jájer, C. Handschin, J. St-Pierre, and B. M. Spiegelman, “AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1α,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 104, no. 29, pp. 12017–12022, 2007.

L. C. Heather, M. A. Cole, H. J. Atherton et al., “Adenosine monophosphate-activated protein kinase activation, substrate transporter translocation, and metabolism in the contracting hyperthyroid rat heart,” *Endocrinology*, vol. 151, no. 1, pp. 422–431, 2010.

L. E. Braverman and R. D. Utiger, “Introduction to thyrotoxicosis,” in *Werner and Ingbar’s The Thyroid*, L. E. Braverman and R. D. Utiger, Eds., pp. 522–524, Lippincott-Raven, Philadelphia, PA, USA, 1996.

V. Fernández, G. Tapia, P. Varela et al., “Redox up-regulated expression of rat liver manganese superoxide dismutase and Bcl-2 by thyroid hormone is associated with inhibitor of kB-α phosphorylation and nuclear factor-kB activation,” *Journal of Endocrinology*, vol. 186, no. 3, pp. 539–547, 2005.

V. Fernández, G. Tapia, P. Varela and L. A. Videla, “Redox regulation of thyroid hormone-induced Kupffer cell-dependent IkB-α phosphorylation in relation to inducible nitric oxide synthase expression,” *Free Radical Research*, vol. 39, no. 4, pp. 411–418, 2005.

G. Tapia, V. Fernández, C. Pino, R. Ardiles, and L. A. Videla, “The acute-phase response of the liver in relation to thyroid hormone-induced redox signaling,” *Free Radical Biology and Medicine*, vol. 40, no. 9, pp. 1628–1635, 2006.

V. Fernández, S. Reyes, S. Bravo et al., “Involvement of Kupffer cell-dependent signaling in T3-induced hepatocyte proliferation in vivo,” *Biological Chemistry*, vol. 388, no. 8, pp. 831–837, 2007.

L. F. Gomes, S. Lorente, K. A. Simon-Giavarotti, K. N. Areco, C. Araújo-Peres, and L. A. Videla, “Tri-iodothyronine differentially induces Kupffer cell ED1/ED2 subpopulations,” *Molecular Aspects of Medicine*, vol. 25, no. 1-2, pp. 183–190, 2004.

H. Jaeschke, “Molecular mechanisms of hepatic ischemia-reperfusion injury and preconditioning,” *American Journal of Physiology, Gastrointestinal and Liver Physiology*, vol. 284, no. 1, pp. G15–G26, 2003.

P. Romanque, M. Uribe, and L. A. Videla, “Mecanismos moleculares en el daño por isquemia-reperfusión hepática y en el preconditionamiento isquémico,” *Revista Médica de Chile*, vol. 133, pp. 469–476, 2005.

M. Massip-salcedo, J. Roselló-Catafau, J. Prieto, M. A. Avila, and C. Peralta, “The response of the hepatocyte to ischemia,” *Molecular Aspects of Medicine*, vol. 284, no. 1, pp. 17–26, 2005.

V. Fernández, G. Tapia, P. Varela et al., “Causal role of oxidative stress in liver preconditioning by thyroid hormone in rats,” *Free Radical Biology and Medicine*, vol. 44, no. 9, pp. 1724–1731, 2008.

J. Zúñiga, F. Venegas, M. Villarreal et al., “Protection against in vivo liver ischemia-reperfusion injury by n-3 long-chain polyunsaturated fatty acids in the rat,” *PLoS One*, vol. 6, no. 12, Article ID e28502, 2011.
[82] M. Mardones, R. Valenzuela, P. Romanque et al., “Prevention of liver ischemia reperfusion injury by a combined thyroid hormone and fish oil protocol,” The Journal of Nutritional Biochemistry. In press.

[83] M. Galleano, G. Tapia, S. Puntarulo, P. Varela, L. A. Videla, and V. Fernández, “Liver preconditioning induced by iron in a rat model of ischemia/reperfusion,” Life Sciences, vol. 89, no. 7-8, pp. 221–228, 2011.

[84] O. De Rougemont, K. Lehmann, and P. A. Clavien, “Preconditioning, organ preservation, and postconditioning to prevent ischemia-reperfusion injury to the liver,” Liver Transplantation, vol. 15, no. 10, pp. 1172–1182, 2009.

[85] U. K. Laemmli, “Cleavage of structural proteins during the assembly of the head of bacteriophage T4,” Nature, vol. 227, no. 5259, pp. 680–685, 1970.

[86] H. Towbin, T. Staehelin, and J. Gordon, “Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications,” Proceedings of the National Academy of Sciences of the United States of America, vol. 76, no. 9, pp. 4350–4354, 1979.